|
EVMS Strelitz Diabetes Center: Endocrine Grand Rounds |
|
|
|
Eastern Virginia Medical School The Strelitz Diabetes Center offers continuing medical education for health professionals. This program includes the weekly “Endocrine Grand Rounds,” recognized by area health professionals as an invaluable resource.
Endocrine Grand Rounds are CME-accredited and are held weekly in the Cosmopolitan Education Classroom at the Strelitz Diabetes Center.
All health professionals are welcome.
|
APRIL 2012
|
|
April 4, 2012
|
Probiotics and a healthy stool: The Cure for Diabetes?
Paul Marik, MD, FCCP, FCCM
Division Chief, Pulmonary and Critical Care Medicine, Professor of Medicine, Department of Internal Medicine, Eastern Virginia Medical School
|
| |
Objective:
1) Assess emerging data showing that the stool bacteria may play a role in diabetes.
General Competency: Medical Knowledge and Patient Care
|
|
April 11, 2012
|
Medical Art Therapy: An Adjunctive Treatment Approach in Diabetes and Other Medical Illnesses
Sarah P. Deaver, PhD, ATR-BC
Associate Professor and Research Director, Graduate Art Therapy and Counseling Program, Eastern Virginia Medical School
|
| |
Objectives:
1) List three advantages of using art therapy as an adjunctive treatment approach for working with individuals with chronic medical illness.
2) Explain the research design, methods, and results of one study of art therapy with women with diabetes.
General Competency: Systems-based Practice and Interpersonal and Communication Skills
|
|
April 18, 2012
|
The Strong Heart Study and SANDS: From Observation to Intervention
William James Howard, MD
Professor of Medicine, Department of Medicine, George Washington University School of Medicine & Health Sciences, Director, Lipid Clinic and Lipid Consultation Services, Washington Hospital Center, Washington DC
|
|
|
Objectives:
1) Recognize the contribution of the Strong Heart Study to our understanding of the significant role of diabetes in the pathogenesis of cardiovascular disease.
2) Discuss the aggressive treatment of hypertension and dyslipidemia in Type 2 Diabetes to reduce cardiovascular risk as illustrated by the SANDS Trial.
3) Implement aggressive treatment of the dyslipidemia of Type 2 Diabetes to reach recommended goals for LDL-C and Non-HDL-C.
General Competency: Medical Knowledge and Patient Care
|
|
April 25, 2012
|
To Be Determined
|
|
|
|
|
|
Last Updated on Friday, 30 March 2012 12:51 |